HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Susanne Jacobsson Selected Research

zoliflodacin

1/2022Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model.
1/2021Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model.
9/2019High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015-2017).
9/2015High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
1/2015Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae.
9/2014High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Susanne Jacobsson Research Topics

Disease

9Infections
06/2022 - 11/2017
6Gonorrhea
01/2022 - 09/2014
5Meningococcal Infections
12/2020 - 03/2009
3Hypersensitivity (Allergy)
09/2019 - 01/2018
1Respiratory Tract Infections (Respiratory Tract Infection)
01/2018
1Sexually Transmitted Diseases (Sexually Transmitted Disease)
01/2015
1Surgical Wound Infection
10/2014

Drug/Important Bio-Agent (IBA)

6zoliflodacinIBA
01/2022 - 09/2014
5Azithromycin (Zithromax)FDA LinkGeneric
06/2022 - 01/2015
5Ceftriaxone (Ceftriaxon)FDA LinkGeneric
01/2022 - 01/2018
3Ciprofloxacin (Cipro)FDA LinkGeneric
06/2022 - 10/2020
2DNA GyraseIBA
01/2022 - 01/2021
2Proteins (Proteins, Gene)FDA Link
01/2020 - 12/2019
2VaccinesIBA
01/2020 - 03/2009
1Doxycycline (Periostat)FDA LinkGeneric
06/2021
1Cefixime (Suprax)FDA Link
03/2021
1Polysaccharides (Glycans)IBA
12/2020
1Capsules (Microcapsules)IBA
12/2020
1RNA (Ribonucleic Acid)IBA
12/2020
1Virulence Factors (Pathogenicity Factors)IBA
12/2020
1InflammasomesIBA
01/2019
1Cephalosporins (Cephalosporin Antibiotics)IBA
01/2018
1FluoroquinolonesIBA
01/2018
1sitafloxacinIBA
01/2018
1gepotidacinIBA
01/2018
1Topoisomerase II InhibitorsIBA
01/2015
1Local Anti-Infective Agents (Antiseptics)IBA
10/2014
1A-Form DNA (A-DNA)IBA
09/2014
1AntigensIBA
03/2009

Therapy/Procedure

2Therapeutics
01/2018 - 01/2018
1Critical Care (Surgical Intensive Care)
01/2021